Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Completed · Phase 1

Conditions studied: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Hodgkin's Lymphoma

In brief

The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.

Key facts

Study ID

NCT01767766

Run by

TG Therapeutics, Inc.

People needed

90

Starts

2013-01-07

Expected to finish

2018-02-01

Last updated by the study team

2021-08-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Refractory to or relapsed after at least 1 prior treatment regimen;
• Eastern Cooperative Oncology Group (ECOG) score of 0 to 2;
• At least 18 years of age.

You may not qualify if…

• Any major surgery, chemotherapy or immunotherapy within the last 21 days (limited palliative radiation is allowed ≥ 2 weeks);
• Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months;
• Known hepatitis B virus, hepatitis C virus or HIV infection;
• Previous therapy with GS-1101 (CAL-101), IPI-145 or any drug that specifically inhibits the PI3K or mTOR pathway;

Where it is running

• TG Therapeutics Trial Site — Sarasota, Florida, United States
• TG Therapeutics Trial Site — Hackensack, New Jersey, United States
• TG Therapeutics Trial Site — New York, New York, United States
• TG Therapeutics Trial Site — Durham, North Carolina, United States
• TG Therapeutics Trial Site — Cincinnati, Ohio, United States
• TG Therapeutics Trial Site — Nashville, Tennessee, United States
• TG Therapeutics Investigational Trial Site — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.